Rallybio Corporaton (RLYB)

$0.59 -0.01 (-2.38%)
Market Cap 25.43M
Revenue (ttm) 640,000.00
Net Income (ttm) -57.78M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -9,028.13%
Debt to Equity Ratio 0.00
Volume 265,700
Avg Vol 3,616,862
Day's Range N/A - N/A
Shares Out 41.79M
Stochastic %K 74%
Beta -1.10
Analysts Sell
Price Target $1.00

Company Profile

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody which is in Phase II clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-tar...

Industry: Biotechnology
Sector: Healthcare
Phone: 203 859 3820
Address:
234 Church Street, Suite 1020, New Haven, United States
Passion_Fruit
Passion_Fruit Sep. 4 at 1:51 PM
$RLYB New here after RXRX payment. Any Longs DD is welcome. Looking to build a position
0 · Reply
TraderGOAT
TraderGOAT Sep. 3 at 7:50 PM
$RLYB Now good on cash with this non-dilutive milestone payment. With this $12.5 million equity payment, Rallybio expects its cash runway to extend through 2027. Data readouts coming this month and in 4th QTR 🤙 Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program https://lifesciencereport.com/news/nasdaq/rlyb/rallybio-receives-12-5-million-equity-milestone-payment-from-recursion-for-advancement-of-rev102-program
0 · Reply
makedatbread88
makedatbread88 Sep. 3 at 4:18 PM
$RLYB news today abnormal volume
0 · Reply
mikedumbledar
mikedumbledar Sep. 3 at 12:26 PM
$RLYB 12.5 million cash added to the balance sheet on a company with a 20 million market cap and its trading lower? hmmm. cash till 2028 and data coming in q3 & q4 2025. this is gonna be a buy watching for entry
1 · Reply
Joesh82
Joesh82 Sep. 3 at 12:16 PM
$RLYB https://investors.rallybio.com/news-releases/news-release-details/rallybio-receives-125-million-equity-milestone-payment-recursion
0 · Reply
stevenryl86
stevenryl86 Sep. 3 at 12:08 PM
$RLYB come 1 dollar ??
0 · Reply
cofhu12twits
cofhu12twits Aug. 21 at 1:48 PM
$RLYB Room for 1.60 pre data imo
1 · Reply
TraderGOAT
TraderGOAT Aug. 18 at 3:02 PM
$RLYB Hit .64 today. Beautiful 👌...keep rising 🤙
0 · Reply
WealthExchange
WealthExchange Aug. 17 at 11:55 PM
$RLYB: Phase 1 data in Q3 2025 and smart money seems to be front running this data.Looking for a run-up into the data release as it’s currently breaking trend towards the upside.Entries between 0.55-.65, SL below 0.45. Key PTs: 0.73, 1, 1.2. Supply above very 0.70s is very light so decent volume could really light this up. 50% insider held 20m float.
0 · Reply
FyCkD__FuNnY
FyCkD__FuNnY Aug. 17 at 7:19 AM
$RLYB Up 8%, Vol under daily avg🤔
0 · Reply
Latest News on RLYB
Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program

Sep 3, 2025, 8:00 AM EDT - 6 days ago

Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program

Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 7, 2025, 8:00 AM EDT - 4 weeks ago

Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates

Why Is Microcap Rallybio Stock Trading Higher On Tuesday?

Jul 8, 2025, 9:44 AM EDT - 2 months ago

Why Is Microcap Rallybio Stock Trading Higher On Tuesday?

Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals

Jul 8, 2025, 8:00 AM EDT - 2 months ago

Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals

Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

Jun 12, 2025, 8:00 AM EDT - 3 months ago

Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates

May 8, 2025, 8:00 AM EDT - 4 months ago

Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates

Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference

Apr 29, 2025, 8:00 AM EDT - 4 months ago

Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference

Rallybio Stock Plunges After Program For Pediatric Bleeding Disorder Disappoints

Apr 8, 2025, 1:01 PM EDT - 5 months ago

Rallybio Stock Plunges After Program For Pediatric Bleeding Disorder Disappoints

Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT

Apr 8, 2025, 8:00 AM EDT - 5 months ago

Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT

Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 13, 2025, 8:00 AM EDT - 6 months ago

Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Rallybio to Present at the TD Cowen 45th Annual Health Care Conference

Feb 25, 2025, 8:00 AM EST - 7 months ago

Rallybio to Present at the TD Cowen 45th Annual Health Care Conference

Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial

Feb 11, 2025, 8:00 AM EST - 7 months ago

Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial

Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025

Jan 10, 2025, 8:00 AM EST - 8 months ago

Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025

Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting

Dec 10, 2024, 8:00 AM EST - 9 months ago

Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting

Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025

Dec 2, 2024, 8:00 AM EST - 10 months ago

Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025

Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women

Nov 27, 2024, 8:00 AM EST - 10 months ago

Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women

Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference

Nov 26, 2024, 8:00 AM EST - 10 months ago

Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference

Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor

Nov 25, 2024, 8:00 AM EST - 10 months ago

Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor

Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212

Nov 21, 2024, 8:00 AM EST - 10 months ago

Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212

Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 7, 2024, 8:00 AM EST - 10 months ago

Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates

Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT

Oct 29, 2024, 8:00 AM EDT - 11 months ago

Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT

Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting

Sep 30, 2024, 8:00 AM EDT - 1 year ago

Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting

Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting

Sep 23, 2024, 8:00 AM EDT - 1 year ago

Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting

Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit

Sep 10, 2024, 8:00 AM EDT - 1 year ago

Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit

Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree

Sep 9, 2024, 5:15 PM EDT - 1 year ago

Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree

Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis

Aug 29, 2024, 8:00 AM EDT - 1 year ago

Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis

National Vision Releases 2023 Sustainability Report

Aug 27, 2024, 8:00 AM EDT - 1 year ago

National Vision Releases 2023 Sustainability Report

ACNT

Rallybio to Present at Upcoming Investor Conferences

Aug 27, 2024, 8:00 AM EDT - 1 year ago

Rallybio to Present at Upcoming Investor Conferences

Rallybio Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Rallybio Reports Second Quarter 2024 Financial Results and Provides Business Updates

Rallybio to Present at the 2024 Jones Healthcare Seaside Summit

Jul 9, 2024, 8:00 AM EDT - 1 year ago

Rallybio to Present at the 2024 Jones Healthcare Seaside Summit

Rallybio Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations

Jun 17, 2024, 8:00 AM EDT - 1 year ago

Rallybio Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations

Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates

May 9, 2024, 8:00 AM EDT - 1 year ago

Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates

Rallybio to Present at the 2024 Citizens JMP Life Sciences Conference

May 7, 2024, 8:00 AM EDT - 1 year ago

Rallybio to Present at the 2024 Citizens JMP Life Sciences Conference

FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting

Apr 17, 2024, 4:01 PM EDT - 1 year ago

FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting

Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Apr 10, 2024, 4:01 PM EDT - 1 year ago

Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Rallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual Meeting

Apr 1, 2024, 10:05 AM EDT - 1 year ago

Rallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual Meeting

Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 12, 2024, 8:00 AM EDT - 1 year ago

Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results

Rallybio to Present at the TD Cowen 44th Annual Health Care Conference

Feb 26, 2024, 8:00 AM EST - 1 year ago

Rallybio to Present at the TD Cowen 44th Annual Health Care Conference

Rallybio Announces Portfolio Prioritization and Provides Corporate Update

Feb 6, 2024, 8:00 AM EST - 1 year ago

Rallybio Announces Portfolio Prioritization and Provides Corporate Update

Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024

Jan 4, 2024, 8:00 AM EST - 1 year ago

Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024

Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5

Dec 20, 2023, 8:00 AM EST - 1 year ago

Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5

Rallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65th American Society of Hematology Annual Meeting

Dec 9, 2023, 12:00 PM EST - 1 year ago

Rallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65th American Society of Hematology Annual Meeting

Rallybio Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212, an Anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia

Nov 28, 2023, 7:00 AM EST - 1 year ago

Rallybio Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212, an Anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia

Rallybio Reports Third Quarter 2023 Financial Results and Provides Business Updates

Nov 9, 2023, 8:00 AM EST - 1 year ago

Rallybio Reports Third Quarter 2023 Financial Results and Provides Business Updates

Rallybio to Present at Upcoming Investor Conferences in November

Nov 8, 2023, 8:00 AM EST - 1 year ago

Rallybio to Present at Upcoming Investor Conferences in November

Rallybio Announces Acceptance of FNAIT Natural History Study Abstract for Presentation at the 65th American Society of Hematology Annual Meeting

Nov 2, 2023, 9:15 AM EDT - 2 years ago

Rallybio Announces Acceptance of FNAIT Natural History Study Abstract for Presentation at the 65th American Society of Hematology Annual Meeting

Rallybio to Present at the JonesTrading 2023 Healthcare Summit

Oct 3, 2023, 8:00 AM EDT - 2 years ago

Rallybio to Present at the JonesTrading 2023 Healthcare Summit

Rallybio: Gearing Up To Be An Opportunity

Sep 15, 2023, 5:15 PM EDT - 2 years ago

Rallybio: Gearing Up To Be An Opportunity

Rallybio Presents Phase 1 Single Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5

Sep 3, 2023, 12:00 PM EDT - 2 years ago

Rallybio Presents Phase 1 Single Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5

Rallybio to Present at Upcoming Investor Conferences in September

Aug 31, 2023, 8:00 AM EDT - 2 years ago

Rallybio to Present at Upcoming Investor Conferences in September

Passion_Fruit
Passion_Fruit Sep. 4 at 1:51 PM
$RLYB New here after RXRX payment. Any Longs DD is welcome. Looking to build a position
0 · Reply
TraderGOAT
TraderGOAT Sep. 3 at 7:50 PM
$RLYB Now good on cash with this non-dilutive milestone payment. With this $12.5 million equity payment, Rallybio expects its cash runway to extend through 2027. Data readouts coming this month and in 4th QTR 🤙 Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program https://lifesciencereport.com/news/nasdaq/rlyb/rallybio-receives-12-5-million-equity-milestone-payment-from-recursion-for-advancement-of-rev102-program
0 · Reply
makedatbread88
makedatbread88 Sep. 3 at 4:18 PM
$RLYB news today abnormal volume
0 · Reply
mikedumbledar
mikedumbledar Sep. 3 at 12:26 PM
$RLYB 12.5 million cash added to the balance sheet on a company with a 20 million market cap and its trading lower? hmmm. cash till 2028 and data coming in q3 & q4 2025. this is gonna be a buy watching for entry
1 · Reply
Joesh82
Joesh82 Sep. 3 at 12:16 PM
$RLYB https://investors.rallybio.com/news-releases/news-release-details/rallybio-receives-125-million-equity-milestone-payment-recursion
0 · Reply
stevenryl86
stevenryl86 Sep. 3 at 12:08 PM
$RLYB come 1 dollar ??
0 · Reply
cofhu12twits
cofhu12twits Aug. 21 at 1:48 PM
$RLYB Room for 1.60 pre data imo
1 · Reply
TraderGOAT
TraderGOAT Aug. 18 at 3:02 PM
$RLYB Hit .64 today. Beautiful 👌...keep rising 🤙
0 · Reply
WealthExchange
WealthExchange Aug. 17 at 11:55 PM
$RLYB: Phase 1 data in Q3 2025 and smart money seems to be front running this data.Looking for a run-up into the data release as it’s currently breaking trend towards the upside.Entries between 0.55-.65, SL below 0.45. Key PTs: 0.73, 1, 1.2. Supply above very 0.70s is very light so decent volume could really light this up. 50% insider held 20m float.
0 · Reply
FyCkD__FuNnY
FyCkD__FuNnY Aug. 17 at 7:19 AM
$RLYB Up 8%, Vol under daily avg🤔
0 · Reply
Dardpro
Dardpro Aug. 15 at 8:00 PM
$RLYB finally!
1 · Reply
FyCkD_FuNnY
FyCkD_FuNnY Aug. 15 at 4:58 PM
$RLYB Up 8%, Vol under daily avg🤔
1 · Reply
Love_To_Learn
Love_To_Learn Aug. 15 at 3:46 PM
$RLYB sit tight need u
0 · Reply
Dardpro
Dardpro Aug. 15 at 3:35 PM
$RLYB so if they don't have enough time to reach 1 anymore by the deadline? What will happen? Move to the other market? Anyone knows?
1 · Reply
Dardpro
Dardpro Aug. 15 at 12:12 PM
$RLYB I sold some yesterday guys, so that means we flying
0 · Reply
eureka
eureka Aug. 14 at 4:06 AM
$RLYB i
1 · Reply
TAMR
TAMR Aug. 11 at 6:58 AM
$RLYB morning folks, smashing through 0.6 this week.
1 · Reply
Dardpro
Dardpro Aug. 8 at 6:55 PM
$RLYB You bipolar duck.
0 · Reply
EyESpy10x
EyESpy10x Aug. 8 at 6:19 PM
$RLYB buyers stepped in on that drop. Rejected.
0 · Reply
DarthGoat
DarthGoat Aug. 8 at 4:54 PM
$RLYB OOOUUTTT +16%
1 · Reply
FyCkD_FuNnY
FyCkD_FuNnY Aug. 7 at 1:03 PM
$RLYB $1.23+/- cash per dhare
1 · Reply
TuJaro
TuJaro Aug. 7 at 12:51 PM
$RLYB How will $RLYB be affected , specify.
0 · Reply